A thought-provoking early-phase trial demonstrates how hypofractionated radiation plus intratumoral BO-112 (i.e., a synthetic mimic of viral genetic material) appears to “reset” the sarcoma immune microenvironment—wiping out existing T cells, activating myeloid cells, and recruiting a new wave of less exhausted, tumor-reactive CD8+ T cells that can generate systemic anti-tumor responses, with the addition of outback PD-1 blockade further amplifying this effect with resulting myositis/myocarditis. | Deng, Cancer Discov 2026
